Rheumatology Practice Management February 2018 Vol 6 No 1
The FDA is taking new steps to promote generic drug competition as part of its ongoing implementation of the Drug Competition Action Plan, according to a statement released by FDA Commissioner Scott Gottlieb, MD, on January 3, 2018.
As nonphysician practitioners (NPPs), such as physician assistants (PAs) and advanced registered nurse practitioners (ARNPs), have started to work in rheumatology practices with greater frequency, it has become increasingly important to understand “incident to” requirements.
Patients with psoriasis are at increased risk for psoriatic arthritis, heart disease, stroke, hypertension, type 2 diabetes, metabolic syndrome, eye disorders, and obesity, as well as for other autoimmune diseases (eg, celiac disease, Crohn’s disease), Parkinson’s disease, and kidney disease.
- Ixekizumab Approved for Adults with Psoriatic Arthritis
- Biosimilar to Infliximab Approved for All Eligible Indications of Reference Drug
- Tofacitinib and Tofacitinib Extended Release Approved for Adults with Psoriatic Arthritis
The following clinical trials represent a selection of key studies that are currently recruiting patients with scleroderma for inclusion in investigations of new therapies and new regimens of existing treatments for individuals with the disease.
As of December 2017, 32 states and the District of Columbia have adopted USP 797 into law, including New Hampshire. Once adopted, a state agency, which is typically the state’s Board of Pharmacy, must be appointed to oversee and enforce these standards.
Results 1 - 6 of 6